Composition comprising n-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity
A technology for acetylcysteine and hyperacidity, applied in the direction of drug combination, application, food science, etc., can solve problems such as patient exposure, achieve the effect of improving efficacy and minimizing drug intake
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2014-08-13
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to a composition comprising N-acetylcysteine and / or lysozyme or N-acetylcysteine and microencapsulated lysozyme in combination with probiotics for the medical treatment of hyperacidity. The composition is capable of restoring the barrier effect of the stomach itself lost during the drug treatment of hyperacidity and minimizing the side effects due to the drug treatment. Furthermore, the presence of N-acetylcysteine, preferably in non-microencapsulated form, in the composition is capable of increasing the efficacy of the probiotics used against pathogens, preferably the presence of microencapsulated and gastroprotective lysozyme Capable of combating excessive bacterial growth and inhibiting the germination of any Clostridium spores present without any type of inhibition involving the probiotic flora. Background technique
[0002] Over the past few decades, various pharmacological approaches have been developed for the ...
Examples
Embodiment Construction
[0034] The applicant has carried out intensive research and selective activities and finally found that a probiotic strain belonging to at least one species selected from the group comprising or alternatively consisting of the following strains is effective for use in the treatment of proton pump inhibitors ( PPI) to reduce or treat subjects with hyperacidity: Lactobacillus acidophilus (L.acidophilus), Lactobacillus crispatus (L.crispatus), Lactobacillus gasseri (L.gasseri), Lactobacillus delbrueckii (L. delbrueckii), L.delbr.subsp.delbrueckii, L.salivarius, L.casei, L.paracasei, plant L. plantarum, L. rhamnosus, L. reuteri, L. brevis, L. buchneri, fermentation L.fermentum, L.lactis, L.pentosus, B.adolescentis, B.angulatum, Bifidobacterium bifidum B.bifidum, B.breve, B.catenulatum, B.infantis, B.lactis, long Bifidobacterium longum, B. pseudocatenulatum and S. thermophilus. Furthermore, the applicant has found that, as a result of the presence of N-acetylcysteine (NAC) in ...